Lower doses of spironolactone are used in practice, and potassium levels and renal function are monitored following the publication that identified increased hyperkalemia-associated morbidity and mortality among patients treated with angiotensin-converting enzyme inhibitors and spironolactone (Juurlink et al., 2004). Here, ACE is linked to Hyperkalemia.